Warm Autoimmune Hemolytic Anemia - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The warm autoimmune hemolytic anemia market size is estimated at USD 0.93 billion in 2026, and is expected to reach USD 1.57 billion by 2031, at a CAGR of 10.85% during the forecast period (2026-2031). This report is Segmented by Drug Class (Corticosteroids, Immunosuppressants, Monoclonal Antibodies, Intravenous Immunoglobulin, Splenectomy & Surgical, Emerging Therapies), End User (Hospitals, Specialty Clinics, Academic & Research Centers), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Warm Autoimmune Hemolytic Anemia Market Trends and Insights

Rising Adoption of Off-Label Biologics

Rituximab is prescribed off-label in close to 40% of second-line cases across North America and Europe, a pattern grounded in randomized data that showed 75% complete responses at 12 months when combined with prednisolone compared with 36% for steroids alone. Growing confidence in anti-CD20 activity now shortens the interval between steroid failure and biologic initiation. Uptake of obinutuzumab and ofatumumab expands the anti-CD20 class as clinicians rotate antibodies to salvage incomplete responders. Splenectomy referrals at tertiary European centers fell by 30% between 2020 and 2025, as durable biologic regimens delayed irreversible surgery. Recognition by the FDA through Breakthrough Therapy status for nipocalimab codifies this off-label momentum by signaling a clear regulatory pathway toward formal indications.

Accelerated FDA Orphan-Drug Incentives

Seven-year exclusivity, tax credits, and fee waivers have spurred a surge in rare-disease filings. Sanofi’s rilzabrutinib received orphan drug designation in April 2025 after Phase 2b data showed 64% hemoglobin response rates without rescue steroids. Comparable incentives in Europe supply 10-year exclusivity, motivating mid-size developers who can recoup costs in small populations. Complement inhibitor pegcetacoplan illustrates both promise and challenge: early signals, yet variable benefit, in an 11-patient cohort underscore how modest sample sizes can compromise statistical power.

Limited Commercial Attractiveness for Big Pharma

Global prevalence of about 17 per 100,000 yields a tiny addressable base, discouraging mega-cap firms that target blockbuster returns. Rigel’s fostamatinib generated only USD 42 million in 2024 despite orphan exclusivity and then failed to meet its Phase 3 endpoint, illustrating financial and clinical risk. Larger companies have diverted resources toward higher-prevalence immunology, leaving room for agile biotechs, yet their smaller sales teams slow penetration in emerging economies.

Other drivers and restraints analyzed in the detailed report include:

• Increasing Autoimmune Prevalence in Aging Cohorts
• Launch of FcRn & Complement Inhibitors
• Diagnostic Complexity & Under-Diagnosis

Segment Analysis

Monoclonal antibodies are projected to grow at 11.07% CAGR from 2026 to 2031, outpacing the overall warm autoimmune hemolytic anemia market. Corticosteroids maintained a 36.81% share in 2025 but now decline as hematologists prize durable remission and reduced toxicity. The Danish trial that combined rituximab with prednisolone delivered a 39-point absolute increase in complete responses, anchoring anti-CD20 agents as standard second-line therapy. Immunosuppressants cede ground as FcRn inhibitors and BTK blockers promise targeted mechanisms with fewer off-target effects. IVIG remains a niche bridge during hemolytic crises, yet plasma shortages limit volume gains. Splenectomy keeps waning because biologics defer irreversible surgery.

Emerging therapies reshape expectations. Sanofi’s oral rilzabrutinib offers convenience that could tilt share if Phase 3 data confirm efficacy and safety. Johnson & Johnson’s nipocalimab introduces an FcRn blueprint that accelerates IgG clearance and may dominate relapsed settings. Pipeline CAR-T constructs aim for one-time cellular re-education, though the feasibility in low-incidence diseases remains to be proven. Collectively, these modalities expand therapeutic options, supporting steady growth in the autoimmune hemolytic anemia market.

Complete Report Scope:

• By Drug Class
  • Corticosteroids
  • Immunosuppressants
  • Monoclonal Antibodies
  • Intravenous Immunoglobulin (IVIG)
  • Splenectomy & Surgical
  • Emerging Therapies
• By End User
  • Hospitals
  • Specialty Clinics
  • Academic & Research Centers
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 41.93 of % warm autoimmune hemolytic anemia market share in 2025, driven by dense academic networks, generous orphan-drug reimbursement, and regulatory frameworks that champion accelerated review. Breakthrough Therapy and orphan designations compress launch timelines, enabling new entrants to reach the market within 18 months of pivotal readout. Canada lags the United States because reimbursement is province-specific, while Mexico’s Seguro Popular adds warm AIHA drugs to essential lists yet grapples with hematologist shortages outside major metros.

Europe has a mature orphan framework with 10-year exclusivity, which supports high prices for low-volume diseases. Germany’s IQWiG deemed rituximab moderately beneficial, strengthening its reimbursement stance, whereas Southern Europe’s tighter budgets curb utilization. The United Kingdom maintains evidence summaries because biosimilars still lack robust AIHA data, which constrains competition. Registry data reveal heterogeneity: only 22% of Italian patients receive rituximab within 6 months of steroid failure, compared with 64% in France, a disparity linked to regional funding envelopes.

Asia-Pacific is forecast to register a 13.03% CAGR from 2026 to 2031, the fastest worldwide. China’s NRDL listing of rituximab biosimilars slashed out-of-pocket expense by 68%, lifting infusion volumes beyond tier-1 cities. Japan issued the region’s first formal warm AIHA rituximab indication in 2024, harmonizing coverage across prefectures. India’s flow cytometry scarcity still drives underdiagnosis, yet private chains invest in hematology centers, thereby shrinking referral delays. Australia reimburses off-label rituximab but requires specialist authorization, which limits rural access.

List of Companies Covered in this Report:

• Amgen
• Amneal Pharmaceuticals
• Apellis Pharma
• Argenx SE
• BioCryst Pharma
• CSL Behring
• Roche
• GlaxoSmithKline
• Grifols
• Johnson & Johnson
• Momenta Pharma
• Novartis
• Pfizer
• Rigel Pharmaceuticals
• Sanofi
• Sobi AB
• Takeda Pharmaceuticals
• UCB

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support